VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
IRWDIronwood Pharmaceuticals, Inc.
$3.54$583M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksIRWDPrice Target
IRWD logo

Ironwood Pharmaceuticals, Inc. (IRWD) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Hold
Based on 30 analysts

35.6% Below Target

IRWD trades 35.6% below Wall Street's consensus target of $4.80.

Current Price$3.54
Average Target$4.80
Target
Current
Low$3.70
Median$5.00
High$5.70

Analyst Target Range

Forward P/E3.0x
(Value)
PEG Ratio—
Implied Growth+92.5%
(High Growth)
Analyst Spread41.7%
(Moderate)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$3.54
Consensus$4.80
High$5.70
Low$3.70

Consensus Scenario Assumptions

The base valuation assumes IRWD achieves its forward estimates and maintains a stable P/E multiple of 3.0x. This scenario reflects the blended consensus of 30 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 30 published analyst recommendations for IRWD

53% hold / mixed conviction
+13
BearishBullish
Weighted analyst sentiment score based on 30 ratings
ConsensusHold
Coverage30 Analysts
Net Score+13
Bull / Bear37% / 10%
Strong Buy00%
Buy1137%
Hold1653%
Sell310%
Strong Sell00%
Strong Buy
00%
Buy
1137%
Hold
1653%
Sell
310%
Strong Sell
00%
Recommendation Mix37% Buy · 53% Hold · 10% Sell
Buy (11)Hold (16)Sell (3)

IRWD Price Target Analysis

Updated June 22, 2026

As of June 22, 2026, Ironwood Pharmaceuticals, Inc. (IRWD) has a Wall Street consensus price target of $4.80, based on estimates from 30 covering analysts. With the stock currently trading at $3.54, this represents a potential upside of +35.6%. The company has a market capitalization of $583M.

Analyst price targets range from a low of $3.70 to a high of $5.70, representing a 42% spread in expectations. The median target of $5.00 aligns closely with the consensus average.

The current analyst consensus rating is Hold, with 11 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 3 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.

From a valuation perspective, IRWD trades at a trailing P/E of 23.6x and forward P/E of 3.0x. Analysts expect EPS to grow +92.5% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $8.74, with bear and bull scenarios of $5.51 and $11.51 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+86.9%
Industry Consensus
Avg Forward P/E
13.7x
(Value)
Peers with Coverage
8 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
PTGX logo
PTGXProtagonist Therapeutics, Inc.
$7.3B$112.86$117.25
+3.9%
Buy28.0x26
ARDX logo
ARDXArdelyx, Inc.
$1.5B$6.05$17.00
+181.0%
Buy—16
CPIX logo
CPIXCumberland Pharmaceuticals Inc.
$86M$5.72—————
SUPN logo
SUPNSupernus Pharmaceuticals, Inc.
$2.6B$44.38$60.00
+35.2%
Buy17.8x14
PRGO logo
PRGOPerrigo Company plc
$1.4B$10.25$36.20
+253.2%
Hold4.8x36
SHPH logo
SHPHShuttle Pharmaceuticals Holdings, Inc.
$2M$3.46—————
VNDA logo
VNDAVanda Pharmaceuticals Inc.
$343M$5.80$14.25
+145.7%
Buy—19
JAZZ logo
JAZZJazz Pharmaceuticals plc
$14.1B$224.66$257.44
+14.6%
Buy8.9x48
PCRX logo
PCRXPacira BioSciences, Inc.
$878M$22.33$32.00
+43.3%
Hold7.8x36
ABBV logo
ABBVAbbVie Inc.
$383.2B$216.63$256.92
+18.6%
Buy15.2x41

IRWD — Frequently Asked Questions

Quick answers to the most common questions about buying IRWD stock.

What is the IRWD stock price target for 2026?

The consensus Wall Street price target for IRWD is $4.8, representing 35.6% upside from the current price of $3.54. With 30 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is IRWD a buy, sell, or hold?

IRWD has a consensus rating of "Hold" based on 30 Wall Street analysts. The rating breakdown is mixed, with 16 Hold ratings making up the largest segment. The consensus 12-month price target of $4.8 implies 35.6% upside from current levels.

Is IRWD stock overvalued or undervalued?

With a forward P/E of 3x, IRWD trades at a relatively low valuation. The consensus target of $4.8 implies 35.6% appreciation, suggesting meaningful undervaluation.

How high can IRWD stock go?

The most bullish Wall Street analyst has a price target of $5.7 for IRWD, while the most conservative target is $3.7. The consensus of $4.8 represents the median expectation. Our quantitative valuation model projects a bull case target of $12 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover IRWD stock?

IRWD is heavily covered by Wall Street, with 30 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 16 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the IRWD stock forecast?

The 12-month IRWD stock forecast based on 30 Wall Street analysts shows a consensus price target of $4.8, with estimates ranging from $3.7 (bear case) to $5.7 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $9, with bear/bull scenarios of $6/$12.

What is IRWD's fair value based on fundamentals?

Our quantitative valuation model calculates IRWD's fair value at $9 (base case), with a bear case of $6 and bull case of $12. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.

What is IRWD's forward P/E ratio?

IRWD trades at a forward P/E ratio of 3.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 23.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy IRWD stock?

Wall Street analysts are very optimistic on IRWD, with a "Hold" consensus rating and $4.8 price target (35.6% upside). 11 of 30 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do IRWD price targets vary so much?

IRWD analyst price targets range from $3.7 to $5.7, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.8 consensus represents the middle ground. Our model's $6-$12 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare